BREO ELLIPTA 200-25 MCG INHALR
FDA nonproprietary name: fluticasone furoate and vilanterol trifenatate
For 1 unit (EA)
Pharmacies pay
$5.36 – $6.50 filed
1 × $5.36203 to $6.502 per EA (the 2 NDCs differ)
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
Medicare Part D paid
$6.50 filed
1 × $6.49963 per EA, Part D average
Medicare's price is not your price.
Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18
The spread
1.0× – 1.2× estimated
Medicare paid between 1.0× and 1.2× what pharmacies pay, depending on the NDC.
Part D averages every strength and form sold under “Breo Ellipta” / “Fluticasone/Vilanterol” into one figure, so it is not specific to this NDC.
OpenBill calculation · DSD_PTD_RY26_P04_V10_DY24_BGM.csv + nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17) · Part D 2024-01-01 to 2024-12-31 (file of 2026-06-25, retrieved 2026-10-18)
Cost-plus estimate
$11.16 – $12.48 estimated
NADAC for the pack + 15% + $5.00 fee per fill
This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out
OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17)
Open the interactive card Change the quantity, type what you were charged, and see every record in full.
What it is
BREO ELLIPTA 200-25 MCG INHALR is how the CMS NADAC file names this product. The FDA NDC Directory lists it as fluticasone furoate and vilanterol trifenatate, under the trade name “Breo Ellipta”.
FDA gives its dosage form as powder and its route as respiratory (inhalation).
The labeler, the company named on the label, is GlaxoSmithKline LLC.
FDA lists it under 2 Established Pharmacologic Classes: beta2-Adrenergic Agonist and Corticosteroid.
The NADAC file of 2026-10-14 prices it under 2 NDCs (National Drug Codes).
NADAC classes it as a brand-name drug (rate-setting class B), and does not mark it as sold over the counter.
What pharmacies pay
Pharmacies pay $5.36 – $6.50 for 1 unit (EA), depending on the NDC ($5.36203 to $6.502 per EA), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.
NADAC’s explanation codes for it: 1, calculated from the most recently completed pharmacy survey; 5, calculated based on package size.
NADAC also lists, on the row of one brand NDC, what pharmacies pay for the generic equivalent, a different product: $3.91371 per EA filed.
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
What NADAC measures · NADAC explanation codes
All 2 NDCs
- 00173-0882-10 · GlaxoSmithKline LLC · $6.502 per EA · eff. 2026-09-23 filed
- 00173-0882-14 · GlaxoSmithKline LLC · $5.36203 per EA · eff. 2026-09-23 filed
Other strengths, forms and brands
2 other products in the NADAC file share the FDA nonproprietary name fluticasone furoate and vilanterol trifenatate with BREO ELLIPTA 200-25 MCG INHALR.
| Product | Pharmacies pay per unit | Medicare per unit |
|---|---|---|
| BREO ELLIPTA 50-25 MCG INHALER | $6.48203 per EA filed | $6.49963 per EA filed |
| BREO ELLIPTA 100-25 MCG INHALR | $5.36105 to $6.49895 per EA filed | $6.49963 per EA filed |
| BREO ELLIPTA 200-25 MCG INHALR this page | $5.36203 to $6.502 per EA filed | $6.49963 per EA filed |
Part D is one average per brand and generic name, over every strength and form.
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18
Compared with its class
The middle of its 2 NDCs’ NADAC prices is $5.36203 per EA filed.
Of the 26 other products in FDA’s beta2-Adrenergic Agonist class priced per EA, 9 have a higher middle NADAC price and 17 a lower one. The one in the middle is FLUTICASONE-VILANTEROL 200-25, at $3.91371 per EA filed (eff. 2026-09-23).
Of the 73 other products in FDA’s Corticosteroid class priced per EA, 25 have a higher middle NADAC price and 48 a lower one. The one in the middle is FLUTICASONE PROP 100 MCG DISKUS, at $2.05252 per EA filed (eff. 2026-09-23).
Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
What Medicare paid
Medicare Part D paid $6.50 for 1 unit (EA), at an average of $6.49963 per EA in 2024 (2024-01-01 to 2024-12-31) for “Breo Ellipta” and “Fluticasone/Vilanterol”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).
That average covers 2,617,269 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.
Medicare's price is not your price.
What Part D spending measures · Which Medicare figure OpenBill compares · How the spread is worked out
What to ask at the counter
None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.
- What is your cash price for 1 unit (EA)? Is it lower than what I would pay through my insurance?
- Which NDC (the 11-digit number on the package) is this? Pharmacies pay $5.36203 to $6.502 per EA for this product, depending on the NDC.
- If you have Medicare Part D: what is my plan’s copay or coinsurance for it? The Part D average on this page is not what you pay.
- These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.
Questions
- Why is the comparison with Medicare for BREO ELLIPTA 200-25 MCG INHALR labelled estimated?
- Beyond what the card shows, the records give these reasons: The Part D figure covers 2024-01-01 to 2024-12-31; the NADAC price is from the file of 2026-10-14. Part D spending basis, as the Part D record states it: Part D 2024 average spend per dosage unit for Breo Ellipta / Fluticasone/Vilanterol: all makers, strengths, forms and routes combined, claim-weighted; gross cost incl. dispensing fees and patient pay, before rebates. Unit taken as NADAC's EA. Joined on brand name.
- Why does this page start at 1 unit (EA)?
- NADAC prices this product per EA, and the FDA NDC Directory lists its 2 NDCs as dosage form “POWDER” with route “RESPIRATORY (INHALATION)”. Only a tablet, capsule, lozenge or troche with route “ORAL”, or a tablet or film with route “SUBLINGUAL” or “BUCCAL”, starts at 30, and none of these is one. NADAC’s EA for it may be a whole package (such as a kit, pen, syringe, vial or inhaler) or one dose inside it, and the files do not say which. So the card starts at 1 unit (EA) rather than guess how many make up a fill; change it to match your prescription.
Related pages
Its pharmacologic classes
Related in the same class
- TRELEGY ELLIPTA 100-62.5-25
- FLUTICASONE-SALMETEROL 100-50
- SYMBICORT 160-4.5 MCG INHALER
- BREZTRI AEROSPHERE 160-9-4.8 MCG
- ADVAIR HFA 115-21 MCG INHALER